1 / 15

Cenicriviroc (CVC): Key Characteristics

Cenicriviroc : A Potent Dual Chemokine Receptor Antagonist (CCR5/CCR2) in Phase 2b Development with Potential to Transform HIV Therapy Sandra M. Palleja, MD 6 th IAS Conference on HIV Pathogenesis-Rome 2011 . ®. Cenicriviroc (CVC): Key Characteristics. Oral CCR5/CCR2 receptor antagonist

kynan
Download Presentation

Cenicriviroc (CVC): Key Characteristics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cenicriviroc: A Potent Dual Chemokine Receptor Antagonist (CCR5/CCR2) in Phase 2b Development with Potential to Transform HIV Therapy Sandra M. Palleja, MD6thIAS Conference on HIV Pathogenesis-Rome 2011 ®

  2. Cenicriviroc (CVC): Key Characteristics • Oral CCR5/CCR2 receptor antagonist • In vitro protein-adjusted EC90 = 1.2 nM (clinical isolates) • CCR2 IC50 = 5.9 nM (inhibition of MCP-1 binding in CHO cells) • Once-daily, oral dosing • Plasma T ½ = 35-40 hours • Additive to synergistic activity with other ART classes in vitro

  3. CVC Key CharacteristicsAttributes Necessary for a Leading HIV Agent • Product profile attributes to be a leading antiviral: potency, once daily oral dosing, safety and barrier to resistance • Well-suited to form QD, fixed-dose-combinations:low dose and long half-life • Unique CCR5/CCR2 dual activity has potential to transform HIV treatment: CV/metabolic benefits to address HIV-associated, inflammation-driven morbidity and mortality CCR5/CCR2 Ideal for QD FDCs Excellent Product Profile Cenicriviroc 3

  4. Unmet Medical Need in HIV • Patients on otherwise effective treatment frequently show persistent immune dysfunction; higher-than-expected risk for non-AIDS-related complications – heart, bone, liver, kidney and neuro-cognitive diseases • HIV+ people on treatment have shorter life expectancy, including those optimally treated • While widely used drugs are generally well-tolerated; short-term toxicities and potential for known and unknown long-termtoxicitiespersist Volberding and Deeks, Lancet July, 2010 4

  5. Cascade of Events Due to Chronic Immune Activation and Inflammation Low-level Viral Replication • Production of pro-inflammatory cytokines possibly due to low level of residual HIV RNA in the virally suppressed patient • Persistent, sustained immune activation and inflammation gradually “burns out” the immune system by depleting the pool of naïve T cells • Progressive decline in the immune function and prolonged inflammation increase the risk of morbidity and mortality from a variety of non-opportunistic conditions Secretion of Pro-inflammatory Cytokines Chronic Inflammation Immune Senescence Osteoporosis, Atherosclerosis, Neurocognitive Degeneration, Frailty, Metabolic Syndrome, etc Appay V, et al. J Pathol. 2008;214:231-241. Hazenburgh MD, et al. AIDS. 2003;17:1881-1888.

  6. The Role of CCR2 in Chronic Inflammation Inflammatory Insult • CCR2 is a chemokine receptor found on the cell surface of monocytes, dendritic cells (immature), and memory T cells • Monocyte chemoattractant protein-1 (MCP-1) is the primary ligand for CCR2 and a potent chemoattractant for monocytes/macrophages Release of MCP-1 Recruitment of Monocytes/Macrophages Release of Inflammatory Cytokines (ie, TNF-α and IL-6) Systemic Inflammatory Response Initiated

  7. New Therapeutic Goals: Suppress Virus and Address Inflammation-Associated Morbidity and Mortality HIV Infection Current HIV Drugs Low level viral replication High level viral replication Cenicriviroc Chronic Inflammation Immune Cell Death AIDS-related morbidities Cardiovascular Disease, Metabolic Syndrome, Premature Aging, etc. Death Death 7

  8. CVC Phase 2a Proof of Concept (POC)Protocol 652-2-201: Trial Design • Objective: To evaluate antiviral potency, safety, tolerability, PK, and CCR2 activity* • Randomized, double-blind, placebo-controlled, dose-escalating study in HIV-infected, CCR5-tropic, treatment experienced patients • 5 dose cohorts: 10-day monotherapy • CVC (n≥8): 25, 50, 75, 100, and 150 mg • Placebo (n=2) • MCP-1 measured on Day 1 and Day 10 * Lalezari, et al. JAIDS June 2011

  9. 25 mg 50 mg 75 mg 150 mg Placebo -0.3 -0.8 -1.6 -1.7 -1.8 CVC Phase 2a: POCEfficacy HIV RNA Median Nadir Change from Baseline* 0 -0.2 -0.4 -0.6 -0.8 HIV RNA Change from Baseline (log10 copies/mL) -1.0 -1.2 -1.4 -1.6 -1.8 -2.0 *Nadir presented because viral load continues to drop after dosing ends.

  10. CVC Phase 2a: POCAntiviral Potency and CCR2 Effect Cenicriviroc Phase 2 – Patient 3007: 100 mg QD for 10 Days

  11. CVC Phase 2b: Protocol 652-2-202Trial Design Arm A: cenicriviroc 100mg + Truvada* (n=60) Arm B: cenicriviroc 200mg + Truvada  (n=60)    Arm C: efavirenz 600mg + Truvada  (n=30) Randomized, double-blind/double-dummy Treatment naïve, CCR5 tropic patients, n=150 Truvada is open label Sites: US and Puerto Rico *Gilead Sciences has provided Truvada for all randomized patients 11

  12. CVC Phase 2b: 652-2-202 Trial Objectives • Primary Endpoints: • Percent of patients with HIV-RNA <50 copies/mL at week 24 • Safety & tolerability of each CVC regimen vs. comparator (SOC) • Secondary Endpoints: • Percent of patients with HIV-RNA <50 copies/mL at week 48, and <400 copies/mL at weeks 24 & 48 • Change from baseline (BL) in HIV-1 RNA at weeks 24 and 48 • Tropism changes and drug resistance in patients with virologic failure • Change from BL in inflammatory biomarkers and immune function at weeks 24 and 48 • Change from BL in metabolic parameters at weeks 24 and 48 12

  13. CVC Phase 2b: 652-2-202 Trial Sub-studies 13

  14. CVC: Summary • Oral, Once-daily dosing (unboosted) • Potent antiviral activity • Phase 2b trial currently underway in HIV-treatment naïve patients to evaluate: • Longer term efficacy and safety • Dose selection for Phase 3 • Concordance between ESTA and genotypic tropism testing • Effect of CCR2 inhibition on inflammatory biomarkers • Unique dual CCR5/CCR2 mechanism has potential for CV/metabolic clinical benefits to address HIV-associated, inflammation-driven morbidity and mortality

  15. “Against AIDS we will prevail together, for we will refuse to be split, or to cast into the shadows those persons, groups and nations that are affected.” – Jonathan Mann

More Related